Outcomes and treatment management of a French cohort suffering from multiple sclerosis: A retrospective epidemiological study
| Autor: | Gilles-Louis Defer, Marianne Payet, Laurène Courouve, J Longin, J. de Seze, S Bouee, A.-S. Jean Deleglise |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male medicine.medical_specialty Pediatrics Multiple Sclerosis Adolescent Kaplan-Meier Estimate Disease Cohort Studies Disability Evaluation Young Adult 03 medical and health sciences Age Distribution 0302 clinical medicine Epidemiology Humans Medicine 030212 general & internal medicine business.industry Multiple sclerosis Disease progression Disease Management General Medicine Middle Aged medicine.disease Natural history Treatment management Treatment Outcome Neurology Multicenter study Cohort Disease Progression Patient Compliance Female France Neurology (clinical) business 030217 neurology & neurosurgery |
| Zdroj: | Multiple Sclerosis and Related Disorders. 25:276-281 |
| ISSN: | 2211-0348 |
| Popis: | Background Despite a recent interest in Real World Data, such studies are scarce in multiple sclerosis (MS) disease. The objective was to describe the patients, disease progression and use of DMDs in France and compare clinical effectiveness of first-line injectable DMDs. Methods We conducted a retrospective multicenter study in France, using data collected by 11 expert centers with the EDMUS software. Results Overall, 15,039 French MS patients were followed for a mean of 11.5 years. Mean age at start of disease was 32 years and 74% were women. After the disease onset, median time to reach EDSS 3 was 11 years and 51.8% of patients were relapse-free 2 years after the disease's onset. The mean delay between onset of disease and initiation of treatment was 5.7 ± 6.9 years. Over time, it decreased from 8.8 ± 7.8 to 0.7 ± 0.7 years for initiation of treatment before 2000 vs. after 2010, respectively. Two years after the initiation of treatment, the persistence rate of injectable disease modifying drugs (DMDs) was 60.7%. The effectiveness of these drugs were quite similar. Conclusion This study brings new insight on the natural history of MS and the use and effectiveness of injectable DMDs in this condition. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect